Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I2CD
|
||||
| Former ID |
DIB019662
|
||||
| Drug Name |
CSC
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H15ClN4O2
|
||||
| InChI |
InChI=1S/C16H15ClN4O2/c1-19-12(8-7-10-5-4-6-11(17)9-10)18-14-13(19)15(22)21(3)16(23)20(14)2/h4-9H,1-3H3/b8-7+
|
||||
| InChIKey |
WBWFIUAVMCNYPG-BQYQJAHWSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
11651274, 12014942, 14826687, 17404956, 24277703, 26753551, 39379597, 46500435, 48334716, 50068033, 50106164, 50106165, 53777499, 56311237, 57361527, 78938635, 85218906, 85240327, 90341368, 91703443, 92098477, 92303917, 103197366, 103944976, 113909107, 121361411, 124749677, 124801101, 134346634, 135076468, 138080082, 163564347, 178102243, 179326524, 226847117, 241376373, 250121572, 252157179, 252451300
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Antagonist | [2] | |
| Adenosine A1 receptor | Target Info | Antagonist | [3] | ||
| Adenosine A2b receptor | Target Info | Antagonist | [4] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholism | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5609). | ||||
| REF 2 | A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101-11. | ||||
| REF 3 | Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem. 1993 May 14;36(10):1333-42. | ||||
| REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.